APO Research
Talk to an analyst

APO RESEARCH · REPORT

Dermatomyositis Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Dermatomyositis Drug Industry Growth and Trends Forecast to 2032

19 December 2025106 pages

Choose your research edition.

Industry ResearchDermatomyositis Drug Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Dermatomyositis Drug Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal Dermatomyositis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Dermatomyositis Drug Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Dermatomyositis Drug Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Dermatomyositis Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Dermatomyositis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Dermatomyositis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Dermatomyositis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Dermatomyositis Drug include Novartis AG, Eli Lilly and Company, Pfizer Inc, Octapharma AG, Neovacs SA, MedImmune LLC, Marathon Pharmaceuticals LLC, KPI Therapeutics Inc and Idera Pharmaceuticals Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Dermatomyositis Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Dermatomyositis Drug market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Dermatomyositis Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Dermatomyositis Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Dermatomyositis Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Dermatomyositis Drug Market by Company

Novartis AG

Eli Lilly and Company

Pfizer Inc

Octapharma AG

Neovacs SA

MedImmune LLC

Marathon Pharmaceuticals LLC

KPI Therapeutics Inc

Idera Pharmaceuticals Inc

Hope Pharmaceuticals Inc

F. Hoffmann-La Roche Ltd

Dermatomyositis Drug Segment by Type

Immune Globulin

Dalazatide

Baricitinib

Abatacept

IMO-8400

Others

Dermatomyositis Drug Segment by Application

Hospital

Clinic

Others

Dermatomyositis Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dermatomyositis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Dermatomyositis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dermatomyositis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Dermatomyositis Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Dermatomyositis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Immune Globulin Table 2. Major Company of Dalazatide Table 3. Major Company of Baricitinib Table 4. Major Company of Abatacept Table 5. Major Company of IMO-8400 Table 6. Major Company of Others Table 7. Global Dermatomyositis Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 8. Global Dermatomyositis Drug Sales by Type (2021-2026) & (K Units) Table 9. Global Dermatomyositis Drug Sales Market Share in Volume by Type (2021-2026) Table 10. Global Dermatomyositis Drug Sales by Type (2021-2026) & (US$ Million) Table 11. Global Dermatomyositis Drug Sales Market Share in Value by Type (2021-2026) Table 12. Global Dermatomyositis Drug Price by Type (2021-2026) & (US$/Unit) Table 13. Global Dermatomyositis Drug Sales by Type (2027-2032) & (K Units) Table 14. Global Dermatomyositis Drug Sales Market Share in Volume by Type (2027-2032) Table 15. Global Dermatomyositis Drug Sales by Type (2027-2032) & (US$ Million) Table 16. Global Dermatomyositis Drug Sales Market Share in Value by Type (2027-2032) Table 17. Global Dermatomyositis Drug Price by Type (2027-2032) & (US$/Unit) Table 18. North America Dermatomyositis Drug Sales by Type (2021-2026) & (K Units) Table 19. North America Dermatomyositis Drug Sales by Type (2021-2026) & (US$ Million) Table 20. Europe Dermatomyositis Drug Sales by Type (2021-2026) & (K Units) Table 21. Europe Dermatomyositis Drug Sales by Type (2021-2026) & (US$ Million) Table 22. Asia-Pacific Dermatomyositis Drug Sales by Type (2021-2026) & (K Units) Table 23. Asia-Pacific Dermatomyositis Drug Sales by Type (2021-2026) & (US$ Million) Table 24. Latin America Dermatomyositis Drug Sales by Type (2021-2026) & (K Units) Table 25. Latin America Dermatomyositis Drug Sales by Type (2021-2026) & (US$ Million) Table 26. Middle East and Africa Dermatomyositis Drug Sales by Type (2021-2026) & (K Units) Table 27. Middle East and Africa Dermatomyositis Drug Sales by Type (2021-2026) & (US$ Million) Table 28. Dermatomyositis Drug Industry Trends Table 29. Dermatomyositis Drug Industry Drivers Table 30. Dermatomyositis Drug Industry Opportunities and Challenges Table 31. Dermatomyositis Drug Industry Restraints Table 32. Global Dermatomyositis Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 33. Global Dermatomyositis Drug Revenue Market Share by Company (2021-2026) Table 34. Global Dermatomyositis Drug Sales by Company (2021-2026) & (K Units) Table 35. Global Dermatomyositis Drug Sales Share by Company (2021-2026) Table 36. Global Dermatomyositis Drug Market Price by Company (2021-2026) & (US$/Unit) Table 37. Global Dermatomyositis Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 38. Global Dermatomyositis Drug Major Company Production Sites and Headquarters Table 39. Global Dermatomyositis Drug Company, Product Type & Application Table 40. Global Dermatomyositis Drug Company Establishment Date Table 41. Global Company Market Concentration Ratio (CR5 and HHI) Table 42. Global Dermatomyositis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 43. Global Dermatomyositis Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 44. Global Dermatomyositis Drug Sales by Region (2021-2026) & (K Units) Table 45. Global Dermatomyositis Drug Sales Market Share in Volume by Region (2021-2026) Table 46. Global Dermatomyositis Drug Sales by Region (2021-2026) & (US$ Million) Table 47. Global Dermatomyositis Drug Sales Market Share in Value by Region (2021-2026) Table 48. Global Dermatomyositis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 49. Global Dermatomyositis Drug Sales by Region (2027-2032) & (K Units) Table 50. Global Dermatomyositis Drug Sales Market Share in Volume by Region (2027-2032) Table 51. Global Dermatomyositis Drug Sales by Region (2027-2032) & (US$ Million) Table 52. Global Dermatomyositis Drug Sales Market Share in Value by Region (2027-2032) Table 53. Global Dermatomyositis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 54. Global Dermatomyositis Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 55. Global Dermatomyositis Drug Sales by Application (2021-2026) & (K Units) Table 56. Global Dermatomyositis Drug Sales Market Share in Volume by Application (2021-2026) Table 57. Global Dermatomyositis Drug Sales by Application (2021-2026) & (US$ Million) Table 58. Global Dermatomyositis Drug Sales Market Share in Value by Application (2021-2026) Table 59. Global Dermatomyositis Drug Price by Application (2021-2026) & (US$/Unit) Table 60. Global Dermatomyositis Drug Sales by Application (2027-2032) & (K Units) Table 61. Global Dermatomyositis Drug Sales Market Share in Volume by Application (2027-2032) Table 62. Global Dermatomyositis Drug Sales by Application (2027-2032) & (US$ Million) Table 63. Global Dermatomyositis Drug Sales Market Share in Value by Application (2027-2032) Table 64. Global Dermatomyositis Drug Price by Application (2027-2032) & (US$/Unit) Table 65. North America Dermatomyositis Drug Sales by Application (2021-2026) & (K Units) Table 66. North America Dermatomyositis Drug Sales by Application (2021-2026) & (US$ Million) Table 67. Europe Dermatomyositis Drug Sales by Application (2021-2026) & (K Units) Table 68. Europe Dermatomyositis Drug Sales by Application (2021-2026) & (US$ Million) Table 69. Asia-Pacific Dermatomyositis Drug Sales by Application (2021-2026) & (K Units) Table 70. Asia-Pacific Dermatomyositis Drug Sales by Application (2021-2026) & (US$ Million) Table 71. Latin America Dermatomyositis Drug Sales by Application (2021-2026) & (K Units) Table 72. Latin America Dermatomyositis Drug Sales by Application (2021-2026) & (US$ Million) Table 73. Middle East and Africa Dermatomyositis Drug Sales by Application (2021-2026) & (K Units) Table 74. Middle East and Africa Dermatomyositis Drug Sales by Application (2021-2026) & (US$ Million) Table 75. Novartis AG Company Information Table 76. Novartis AG Business Overview Table 77. Novartis AG Dermatomyositis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Novartis AG Dermatomyositis Drug Product Portfolio Table 79. Novartis AG Recent Development Table 80. Eli Lilly and Company Company Information Table 81. Eli Lilly and Company Business Overview Table 82. Eli Lilly and Company Dermatomyositis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Eli Lilly and Company Dermatomyositis Drug Product Portfolio Table 84. Eli Lilly and Company Recent Development Table 85. Pfizer Inc Company Information Table 86. Pfizer Inc Business Overview Table 87. Pfizer Inc Dermatomyositis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Pfizer Inc Dermatomyositis Drug Product Portfolio Table 89. Pfizer Inc Recent Development Table 90. Octapharma AG Company Information Table 91. Octapharma AG Business Overview Table 92. Octapharma AG Dermatomyositis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Octapharma AG Dermatomyositis Drug Product Portfolio Table 94. Octapharma AG Recent Development Table 95. Neovacs SA Company Information Table 96. Neovacs SA Business Overview Table 97. Neovacs SA Dermatomyositis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Neovacs SA Dermatomyositis Drug Product Portfolio Table 99. Neovacs SA Recent Development Table 100. MedImmune LLC Company Information Table 101. MedImmune LLC Business Overview Table 102. MedImmune LLC Dermatomyositis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. MedImmune LLC Dermatomyositis Drug Product Portfolio Table 104. MedImmune LLC Recent Development Table 105. Marathon Pharmaceuticals LLC Company Information Table 106. Marathon Pharmaceuticals LLC Business Overview Table 107. Marathon Pharmaceuticals LLC Dermatomyositis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Marathon Pharmaceuticals LLC Dermatomyositis Drug Product Portfolio Table 109. Marathon Pharmaceuticals LLC Recent Development Table 110. KPI Therapeutics Inc Company Information Table 111. KPI Therapeutics Inc Business Overview Table 112. KPI Therapeutics Inc Dermatomyositis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. KPI Therapeutics Inc Dermatomyositis Drug Product Portfolio Table 114. KPI Therapeutics Inc Recent Development Table 115. Idera Pharmaceuticals Inc Company Information Table 116. Idera Pharmaceuticals Inc Business Overview Table 117. Idera Pharmaceuticals Inc Dermatomyositis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Idera Pharmaceuticals Inc Dermatomyositis Drug Product Portfolio Table 119. Idera Pharmaceuticals Inc Recent Development Table 120. Hope Pharmaceuticals Inc Company Information Table 121. Hope Pharmaceuticals Inc Business Overview Table 122. Hope Pharmaceuticals Inc Dermatomyositis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Hope Pharmaceuticals Inc Dermatomyositis Drug Product Portfolio Table 124. Hope Pharmaceuticals Inc Recent Development Table 125. F. Hoffmann-La Roche Ltd Company Information Table 126. F. Hoffmann-La Roche Ltd Business Overview Table 127. F. Hoffmann-La Roche Ltd Dermatomyositis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. F. Hoffmann-La Roche Ltd Dermatomyositis Drug Product Portfolio Table 129. F. Hoffmann-La Roche Ltd Recent Development Table 130. North America Dermatomyositis Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 131. North America Dermatomyositis Drug Sales by Country (2021-2026) & (K Units) Table 132. North America Dermatomyositis Drug Sales Market Share by Country (2021-2026) Table 133. North America Dermatomyositis Drug Sales Forecast by Country (2027-2032) & (K Units) Table 134. North America Dermatomyositis Drug Sales Market Share Forecast by Country (2027-2032) Table 135. North America Dermatomyositis Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 136. North America Dermatomyositis Drug Market Size by Country (2021-2026) & (US$ Million) Table 137. North America Dermatomyositis Drug Market Share by Country (2021-2026) Table 138. North America Dermatomyositis Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 139. North America Dermatomyositis Drug Market Share Forecast by Country (2027-2032) Table 140. Europe Dermatomyositis Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 141. Europe Dermatomyositis Drug Sales by Country (2021-2026) & (K Units) Table 142. Europe Dermatomyositis Drug Sales Market Share by Country (2021-2026) Table 143. Europe Dermatomyositis Drug Sales Forecast by Country (2027-2032) & (K Units) Table 144. Europe Dermatomyositis Drug Sales Market Share Forecast by Country (2027-2032) Table 145. Europe Dermatomyositis Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 146. Europe Dermatomyositis Drug Market Size by Country (2021-2026) & (US$ Million) Table 147. Europe Dermatomyositis Drug Market Share by Country (2021-2026) Table 148. Europe Dermatomyositis Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 149. Europe Dermatomyositis Drug Market Share Forecast by Country (2027-2032) Table 150. Asia-Pacific Dermatomyositis Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 151. Asia-Pacific Dermatomyositis Drug Sales by Country (2021-2026) & (K Units) Table 152. Asia-Pacific Dermatomyositis Drug Sales Market Share by Country (2021-2026) Table 153. Asia-Pacific Dermatomyositis Drug Sales Forecast by Country (2027-2032) & (K Units) Table 154. Asia-Pacific Dermatomyositis Drug Sales Market Share Forecast by Country (2027-2032) Table 155. Asia-Pacific Dermatomyositis Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 156. Asia-Pacific Dermatomyositis Drug Market Size by Country (2021-2026) & (US$ Million) Table 157. Asia-Pacific Dermatomyositis Drug Market Share by Country (2021-2026) Table 158. Asia-Pacific Dermatomyositis Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 159. Asia-Pacific Dermatomyositis Drug Market Share Forecast by Country (2027-2032) Table 160. Latin America Dermatomyositis Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 161. Latin America Dermatomyositis Drug Sales by Country (2021-2026) & (K Units) Table 162. Latin America Dermatomyositis Drug Sales Market Share by Country (2021-2026) Table 163. Latin America Dermatomyositis Drug Sales Forecast by Country (2027-2032) & (K Units) Table 164. Latin America Dermatomyositis Drug Sales Market Share Forecast by Country (2027-2032) Table 165. Latin America Dermatomyositis Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 166. Latin America Dermatomyositis Drug Market Size by Country (2021-2026) & (US$ Million) Table 167. Latin America Dermatomyositis Drug Market Share by Country (2021-2026) Table 168. Latin America Dermatomyositis Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 169. Latin America Dermatomyositis Drug Market Share Forecast by Country (2027-2032) Table 170. Middle East and Africa Dermatomyositis Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 171. Middle East and Africa Dermatomyositis Drug Sales by Country (2021-2026) & (K Units) Table 172. Middle East and Africa Dermatomyositis Drug Sales Market Share by Country (2021-2026) Table 173. Middle East and Africa Dermatomyositis Drug Sales Forecast by Country (2027-2032) & (K Units) Table 174. Middle East and Africa Dermatomyositis Drug Sales Market Share Forecast by Country (2027-2032) Table 175. Middle East and Africa Dermatomyositis Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 176. Middle East and Africa Dermatomyositis Drug Market Size by Country (2021-2026) & (US$ Million) Table 177. Middle East and Africa Dermatomyositis Drug Market Share by Country (2021-2026) Table 178. Middle East and Africa Dermatomyositis Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 179. Middle East and Africa Dermatomyositis Drug Market Share Forecast by Country (2027-2032) Table 180. Key Raw Materials Table 181. Raw Materials Key Suppliers Table 182. Dermatomyositis Drug Distributors List Table 183. Dermatomyositis Drug Customers List Table 184. Research Programs/Design for This Report Table 185. Authors List of This Report Table 186. Secondary Sources Table 187. Primary Sources List of Figures Figure 1. Dermatomyositis Drug Image Figure 2. Global Dermatomyositis Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Dermatomyositis Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Dermatomyositis Drug Sales (2021-2032) & (K Units) Figure 5. Immune Globulin Image Figure 6. Global Immune Globulin Sales YoY Growth (2021-2032) & (K Units) Figure 7. Dalazatide Image Figure 8. Global Dalazatide Sales YoY Growth (2021-2032) & (K Units) Figure 9. Baricitinib Image Figure 10. Global Baricitinib Sales YoY Growth (2021-2032) & (K Units) Figure 11. Abatacept Image Figure 12. Global Abatacept Sales YoY Growth (2021-2032) & (K Units) Figure 13. IMO-8400 Image Figure 14. Global IMO-8400 Sales YoY Growth (2021-2032) & (K Units) Figure 15. Others Image Figure 16. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 17. Global Dermatomyositis Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 18. Global Dermatomyositis Drug Market Share by Type 2025 VS 2032 Figure 19. North America Dermatomyositis Drug Sales Market Share in Volume by Type in 2025 Figure 20. North America Dermatomyositis Drug Sales Market Share in Value by Type in 2025 Figure 21. Europe Dermatomyositis Drug Sales Market Share in Volume by Type in 2025 Figure 22. Europe Dermatomyositis Drug Sales Market Share in Value by Type in 2025 Figure 23. Asia-Pacific Dermatomyositis Drug Sales Market Share in Volume by Type in 2025 Figure 24. Asia-Pacific Dermatomyositis Drug Sales Market Share in Value by Type in 2025 Figure 25. Latin America Dermatomyositis Drug Sales Market Share in Volume by Type in 2025 Figure 26. Latin America Dermatomyositis Drug Sales Market Share in Value by Type in 2025 Figure 27. Middle East and Africa Dermatomyositis Drug Sales Market Share in Volume by Type in 2025 Figure 28. Middle East and Africa Dermatomyositis Drug Sales Market Share in Value by Type in 2025 Figure 29. Global Top 5 and 10 Dermatomyositis Drug Players Market Share by Revenue in 2025 Figure 30. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Hospital Image Figure 32. Global Hospital Sales YoY Growth (2021-2032) & (K Units) Figure 33. Clinic Image Figure 34. Global Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 35. Others Image Figure 36. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 37. Global Dermatomyositis Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 38. Global Dermatomyositis Drug Market Share by Application 2025 VS 2032 Figure 39. North America Dermatomyositis Drug Sales Market Share in Volume by Application in 2025 Figure 40. North America Dermatomyositis Drug Sales Market Share in Value by Application in 2025 Figure 41. Europe Dermatomyositis Drug Sales Market Share in Volume by Application in 2025 Figure 42. Europe Dermatomyositis Drug Sales Market Share in Value by Application in 2025 Figure 43. Asia-Pacific Dermatomyositis Drug Sales Market Share in Volume by Application in 2025 Figure 44. Asia-Pacific Dermatomyositis Drug Sales Market Share in Value by Application in 2025 Figure 45. Latin America Dermatomyositis Drug Sales Market Share in Volume by Application in 2025 Figure 46. Latin America Dermatomyositis Drug Sales Market Share in Value by Application in 2025 Figure 47. Middle East and Africa Dermatomyositis Drug Sales Market Share in Volume by Application in 2025 Figure 48. Middle East and Africa Dermatomyositis Drug Sales Market Share in Value by Application in 2025 Figure 49. North America Dermatomyositis Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. North America Dermatomyositis Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. North America Dermatomyositis Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. North America Dermatomyositis Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Dermatomyositis Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Europe Dermatomyositis Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe Dermatomyositis Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Europe Dermatomyositis Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Dermatomyositis Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Asia-Pacific Dermatomyositis Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific Dermatomyositis Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Asia-Pacific Dermatomyositis Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Dermatomyositis Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 62. Latin America Dermatomyositis Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America Dermatomyositis Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Latin America Dermatomyositis Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Dermatomyositis Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 66. Middle East and Africa Dermatomyositis Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa Dermatomyositis Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 68. Middle East and Africa Dermatomyositis Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 69. Dermatomyositis Drug Value Chain Figure 70. Key Raw Materials Price Figure 71. Manufacturing Cost Structure Figure 72. Dermatomyositis Drug Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Immune Globulin
  • Dalazatide
  • Baricitinib
  • Abatacept
  • IMO-8400
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Novartis AG
  • Eli Lilly and Company
  • Pfizer Inc
  • Octapharma AG
  • Neovacs SA
  • MedImmune LLC
  • Marathon Pharmaceuticals LLC
  • KPI Therapeutics Inc
  • Idera Pharmaceuticals Inc
  • Hope Pharmaceuticals Inc
  • F. Hoffmann-La Roche Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Dermatomyositis Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Dermatomyositis Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Dermatomyositis Drug Market by Type
  6. 1.3.1 Immune Globulin
  7. 1.3.2 Dalazatide
  8. 1.3.3 Baricitinib
  9. 1.3.4 Abatacept
  10. 1.3.5 IMO-8400
  11. 1.3.6 Others
  12. 1.4 Global Dermatomyositis Drug Market Size by Type
  13. 1.4.1 Global Dermatomyositis Drug Market Size Overview by Type (2021-2032)
  14. 1.4.2 Global Dermatomyositis Drug Historic Market Size Review by Type (2021-2026)
  15. 1.4.3 Global Dermatomyositis Drug Forecasted Market Size by Type (2027-2032)
  16. 1.5 Key Regions Market Size by Type
  17. 1.5.1 North America Dermatomyositis Drug Sales Breakdown by Type (2021-2026)
  18. 1.5.2 Europe Dermatomyositis Drug Sales Breakdown by Type (2021-2026)
  19. 1.5.3 Asia-Pacific Dermatomyositis Drug Sales Breakdown by Type (2021-2026)
  20. 1.5.4 South America Dermatomyositis Drug Sales Breakdown by Type (2021-2026)
  21. 1.5.5 Middle East and Africa Dermatomyositis Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Dermatomyositis Drug Industry Trends
  2. 2.2 Dermatomyositis Drug Industry Drivers
  3. 2.3 Dermatomyositis Drug Industry Opportunities and Challenges
  4. 2.4 Dermatomyositis Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Dermatomyositis Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Dermatomyositis Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Dermatomyositis Drug Price (2021-2026)
  4. 3.4 Global Dermatomyositis Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Dermatomyositis Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Dermatomyositis Drug Company, Product Type & Application
  7. 3.7 Global Dermatomyositis Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Dermatomyositis Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Dermatomyositis Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Dermatomyositis Drug Tier 1, Tier 2, and Tier 3
4 Dermatomyositis Drug Regional Status and Outlook
  1. 4.1 Global Dermatomyositis Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Dermatomyositis Drug Historic Market Size by Region
  3. 4.2.1 Global Dermatomyositis Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Dermatomyositis Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Dermatomyositis Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Dermatomyositis Drug Forecasted Market Size by Region
  7. 4.3.1 Global Dermatomyositis Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Dermatomyositis Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Dermatomyositis Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Dermatomyositis Drug by Application
  1. 5.1 Dermatomyositis Drug Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Dermatomyositis Drug Market Size by Application
  6. 5.2.1 Global Dermatomyositis Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Dermatomyositis Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Dermatomyositis Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Dermatomyositis Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Dermatomyositis Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Dermatomyositis Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Dermatomyositis Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Dermatomyositis Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Novartis AG
  2. 6.1.1 Novartis AG Company Information
  3. 6.1.2 Novartis AG Business Overview
  4. 6.1.3 Novartis AG Dermatomyositis Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Novartis AG Dermatomyositis Drug Product Portfolio
  6. 6.1.5 Novartis AG Recent Developments
  7. 6.2 Eli Lilly and Company
  8. 6.2.1 Eli Lilly and Company Company Information
  9. 6.2.2 Eli Lilly and Company Business Overview
  10. 6.2.3 Eli Lilly and Company Dermatomyositis Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Eli Lilly and Company Dermatomyositis Drug Product Portfolio
  12. 6.2.5 Eli Lilly and Company Recent Developments
  13. 6.3 Pfizer Inc
  14. 6.3.1 Pfizer Inc Company Information
  15. 6.3.2 Pfizer Inc Business Overview
  16. 6.3.3 Pfizer Inc Dermatomyositis Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Pfizer Inc Dermatomyositis Drug Product Portfolio
  18. 6.3.5 Pfizer Inc Recent Developments
  19. 6.4 Octapharma AG
  20. 6.4.1 Octapharma AG Company Information
  21. 6.4.2 Octapharma AG Business Overview
  22. 6.4.3 Octapharma AG Dermatomyositis Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Octapharma AG Dermatomyositis Drug Product Portfolio
  24. 6.4.5 Octapharma AG Recent Developments
  25. 6.5 Neovacs SA
  26. 6.5.1 Neovacs SA Company Information
  27. 6.5.2 Neovacs SA Business Overview
  28. 6.5.3 Neovacs SA Dermatomyositis Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Neovacs SA Dermatomyositis Drug Product Portfolio
  30. 6.5.5 Neovacs SA Recent Developments
  31. 6.6 MedImmune LLC
  32. 6.6.1 MedImmune LLC Company Information
  33. 6.6.2 MedImmune LLC Business Overview
  34. 6.6.3 MedImmune LLC Dermatomyositis Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 MedImmune LLC Dermatomyositis Drug Product Portfolio
  36. 6.6.5 MedImmune LLC Recent Developments
  37. 6.7 Marathon Pharmaceuticals LLC
  38. 6.7.1 Marathon Pharmaceuticals LLC Company Information
  39. 6.7.2 Marathon Pharmaceuticals LLC Business Overview
  40. 6.7.3 Marathon Pharmaceuticals LLC Dermatomyositis Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Marathon Pharmaceuticals LLC Dermatomyositis Drug Product Portfolio
  42. 6.7.5 Marathon Pharmaceuticals LLC Recent Developments
  43. 6.8 KPI Therapeutics Inc
  44. 6.8.1 KPI Therapeutics Inc Company Information
  45. 6.8.2 KPI Therapeutics Inc Business Overview
  46. 6.8.3 KPI Therapeutics Inc Dermatomyositis Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 KPI Therapeutics Inc Dermatomyositis Drug Product Portfolio
  48. 6.8.5 KPI Therapeutics Inc Recent Developments
  49. 6.9 Idera Pharmaceuticals Inc
  50. 6.9.1 Idera Pharmaceuticals Inc Company Information
  51. 6.9.2 Idera Pharmaceuticals Inc Business Overview
  52. 6.9.3 Idera Pharmaceuticals Inc Dermatomyositis Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Idera Pharmaceuticals Inc Dermatomyositis Drug Product Portfolio
  54. 6.9.5 Idera Pharmaceuticals Inc Recent Developments
  55. 6.10 Hope Pharmaceuticals Inc
  56. 6.10.1 Hope Pharmaceuticals Inc Company Information
  57. 6.10.2 Hope Pharmaceuticals Inc Business Overview
  58. 6.10.3 Hope Pharmaceuticals Inc Dermatomyositis Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Hope Pharmaceuticals Inc Dermatomyositis Drug Product Portfolio
  60. 6.10.5 Hope Pharmaceuticals Inc Recent Developments
  61. 6.11 F. Hoffmann-La Roche Ltd
  62. 6.11.1 F. Hoffmann-La Roche Ltd Company Information
  63. 6.11.2 F. Hoffmann-La Roche Ltd Business Overview
  64. 6.11.3 F. Hoffmann-La Roche Ltd Dermatomyositis Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 F. Hoffmann-La Roche Ltd Dermatomyositis Drug Product Portfolio
  66. 6.11.5 F. Hoffmann-La Roche Ltd Recent Developments
7 North America by Country
  1. 7.1 North America Dermatomyositis Drug Sales by Country
  2. 7.1.1 North America Dermatomyositis Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Dermatomyositis Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Dermatomyositis Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Dermatomyositis Drug Market Size by Country
  6. 7.2.1 North America Dermatomyositis Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Dermatomyositis Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Dermatomyositis Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Dermatomyositis Drug Sales by Country
  2. 8.1.1 Europe Dermatomyositis Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Dermatomyositis Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Dermatomyositis Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Dermatomyositis Drug Market Size by Country
  6. 8.2.1 Europe Dermatomyositis Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Dermatomyositis Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Dermatomyositis Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Dermatomyositis Drug Sales by Country
  2. 9.1.1 Asia-Pacific Dermatomyositis Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Dermatomyositis Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Dermatomyositis Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Dermatomyositis Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Dermatomyositis Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Dermatomyositis Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Dermatomyositis Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Dermatomyositis Drug Sales by Country
  2. 10.1.1 South America Dermatomyositis Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Dermatomyositis Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Dermatomyositis Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Dermatomyositis Drug Market Size by Country
  6. 10.2.1 South America Dermatomyositis Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Dermatomyositis Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Dermatomyositis Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Dermatomyositis Drug Sales by Country
  2. 11.1.1 Middle East and Africa Dermatomyositis Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Dermatomyositis Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Dermatomyositis Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Dermatomyositis Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Dermatomyositis Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Dermatomyositis Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Dermatomyositis Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Dermatomyositis Drug Value Chain Analysis
  2. 12.1.1 Dermatomyositis Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Dermatomyositis Drug Production Mode & Process
  7. 12.2 Dermatomyositis Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Dermatomyositis Drug Distributors
  10. 12.2.3 Dermatomyositis Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst